SLIGRL-NH2 TFA

Cat. No.:	HY-P1308A
Molecular Formula:	$C_{31}H_{57}F_3N_{10}O_9$
Molecular Weight:	770.84
Sequence:	Ser-Leu-Ile-Gly-Arg-Leu-NH2
Sequence Shortening:	SLIGRL-NH2
Target:	Protease-Activated Receptor (PAR)
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SLIGRL-NH2 TFA (Protease-Activated Receptor-2 Activating Peptide TFA) is an agonist of Protease-Activated Receptor-2 (PAR-2)[1].
IC_{50} & Target	PAR-2[1]
In Vitro	SLIGRL-NH2 is an agonist of PAR-2 and MrgprC11[1]. SLIGRL-NH2 causes an L-NAME-inhibited relaxation. Based on SLIGRL-NH_2 causing a concentration-dependent relaxation with an EC_{50} of 10 μM in endothelium-free preparations in the presence of perivascular adipose tissue (PVAT) , 20 μM is used as a suitable 'test' concentration of peptide in subsequent experiments designed to evaluate the effects of potential inhibitors of ADRF release/action. In the endothelium-free aorta preparations, SLIGRL-NH2 causes a concentration-dependent relaxation in preparations only in the presence of PVAT [+PVAT, -ENDO (endothelium)][2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Akiyama T, et al. Behavioral model of itch, alloknesis, pain and allodynia in the lower hindlimb and correlativeresponses of lumbar dorsal horn neurons in the mouse. Neuroscience. 2014 Apr 25;266:38-46.

[2]. Li Y, et al. Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. Br J Pharmacol. 2011 Dec;164(8):1990-2002.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA